Männedorf, Switzerland, September 10, 2026 – The Tecan Group (SIX Swiss Exchange: TECN) today announced that it will participate in the following investor conference next week:

24th Annual Morgan Stanley Healthcare Conference, New York, USA
Date: September 14, 2026
Time: 2:35pm EDT (8:35pm CEST)
Format: Fireside chat with Monica Manotas, CEO, and the Morgan Stanley analyst
Additional participants: Camila Japur, CFO & Martin Braendle, SVP, Corp. Comm. & Investor Relations
Webcast live under the “Investor Relations” tab of Tecan’s website www.tecan.com.
A replay of the webcast will be available after the presentation and will remain available for 120 days.

About Tecan

Tecan (www.tecan.com) improves people’s lives and health by empowering customers to scale healthcare innovation globally from life science to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments, components and medical devices that are then distributed by partner companies. Founded in Switzerland in 1980, the company has more than 3,000 employees, with manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in over 70 countries. In 2025, Tecan generated sales of CHF 883 million (USD 1,063 million; EUR 939 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
        
        
For further information:

Tecan Group
Martin Brändle
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com

Attachment

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

CALGARY, Alberta, Sept. 10, 2026 (GLOBE NEWSWIRE) — Reconnaissance Energy Africa Ltd. (the “Company” or “ReconAfrica”) (TSXV: RECO) (OTCQX: RECAF) (Frankfurt: 0XD) (NSX: REC) is pleased to announce that it has completed its previously announced and upsized bought-deal public offering (the “Offering”) of 29,932,200 units of the Company (the “Units”) at a price of C$0.73 per Unit for aggregate gross proceeds to the Company of C$21,850,506, including the full exercise of the over-allotment option.

The Offering was led by Research Capital Corporation as the lead underwriter and sole bookrunner, on behalf of a syndicate of underwriters, including Canaccord Genuity Corp. and ATB Cormark Capital Markets (collectively, the “Underwriters”).

Each Unit is comprised of one common share of the Company (a “Common Share”) and one-half of one common share purchase warrant of the Company (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share (a “Warrant Share”) at an exercise price of C$0.93 until September 10, 2029. The Warrants are expected to commence trading on the TSX Venture Exchange (“TSXV”) under the symbol “RECO.WT.D” in the following week, subject to final TSXV acceptance.

The net proceeds from the Offering will be used for conducting an open-hole horizontal sidetrack and production testing program, targeting the primary reservoir in the Huttenberg formation and/or the secondary reservoir in the Elandshoek formation, and for general corporate purposes and working capital.

The Offering was completed by way of a prospectus supplement, to the Company’s short form base shelf prospectus dated April 13, 2026, with the securities regulatory authorities in each of the provinces of Canada (except Québec). Copies of the base shelf prospectus and any supplement thereto to be filed in connection with the Offering, are available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

In connection with the Offering, the Company paid the Underwriters an aggregate cash commission of C$1,282,910.76 and issued to the Underwriters an aggregate of 1,757,412 broker warrants (the “Broker Warrants”). The Underwriters also received an aggregate advisory fee of C$15,000 and an aggregate of 6,000 advisory warrants on the same terms as the Broker Warrants. Each Broker Warrant entitles the holder thereof to acquire one Common Share at a price of C$0.73 until September 10, 2029.

This press release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.

About ReconAfrica

ReconAfrica is a Canadian oil and gas company engaged in the exploration of the Damara Fold Belt and Kavango Rift Basin in the Kalahari Desert of northeastern Namibia, southeastern Angola and northwestern Botswana, where the Company holds petroleum licences and access to ~13 million contiguous acres. The Company also operates the Ngulu block in the shallow waters offshore central Gabon covering 1,214 Km2 (equivalent to 54 Gulf of Mexico blocks) which is strategically located near producing oil fields and infrastructure. The Ngulu block includes the Loba oil field discovery and a large inventory of high impact prospects in the pre-salt and post-salt plays. In all aspects of its operations, ReconAfrica is committed to minimal disturbance of habitat in line with international standards and implementing environmental and social best practices in its project areas.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

For further information contact:

Brian Reinsborough, President & Chief Executive Officer
Mark Friesen, Vice President, Investor Relations & Capital Markets

IR Inquiries Email: investors@reconafrica.com
Media Inquiries Email: media@reconafrica.com
Tel: +1-877-631-1160

Cautionary Note Regarding Forward-Looking Statements:

Certain statements contained in this press release constitute forward-looking information under applicable Canadian, United States and other applicable securities laws, rules and regulations, including, without limitation, statements with respect to the expected use of proceeds from the Offering, the trading of the Warrants on the TSXV and the Company’s commitment to minimal disturbances in line with international best standards and its implementation of environmental and social best practices in all of its project areas. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “potential”, “estimated”, “significant” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on ReconAfrica’s current beliefs or assumptions as to the outcome and timing of such future events. There can be no assurance that such statements will prove to be accurate, as the Company’s actual results and future events could differ materially from those anticipated in these forward-looking statements as a result of the factors discussed in the “Risk Factors” section in the Company’s annual information form (“AIF”) dated April 14, 2026, for the financial period ended December 31, 2025, available under the Company’s profile at www.sedarplus.ca. Actual future results may differ materially. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to ReconAfrica. The forward-looking information contained in this release is made as of the date hereof and ReconAfrica undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Appointment strengthens feasibility study execution and advances ARR’s pathway to producing separated rare earth oxides in Wyoming

HIGHLIGHTS

  • Dr. Sanja Miskovic appointed Chief Technical Advisor, joining ARR’s technical leadership team effective immediately
  • Will guide flowsheet development, recovery optimisation and process scale-up activities supporting separated rare earth oxide production in Wyoming
  • More than 20 years of minerals processing, beneficiation, extraction and critical materials experience
  • Supports ARR’s strategy to establish a domestic U.S. mine-to-magnet supply chain

DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) — American Rare Earths Limited (ASX: ARR | OTCQX: ARRNF | ADR: AMRRY) (“ARR” or “the Company”) is pleased to announce the appointment of Dr. Sanja Miskovic as Chief Technical Advisor, effective immediately.

TECHNICAL LEADERSHIP APPOINTMENT STRENGTHENS ARR’S PATH TO SEPARATED RARE EARTH OXIDES

Dr. Miskovic will focus on process and recovery optimization as part of the feasibility study for the Company’s flagship Halleck Creek Rare Earths Project in Wyoming, USA. In this role, she will guide flowsheet development, beneficiation and hydrometallurgical recovery, and scale up decisions that support the production of separated rare earth oxides at the planned Wyoming processing site.

TWO DECADES OF PROCESS ENGINEERING AND CRITICAL MINERALS EXPERIENCE

Dr. Miskovic is a minerals and process engineering expert with more than 20 years of experience spanning academic and industrial research and development. Her expertise includes the development, design, optimization, and scale up of technologies for mineral beneficiation, chemical extraction, pyrometallurgical and thermal processing, and critical materials recovery.

Her career has covered energy and water efficient mineral liberation and concentration, metal extraction, purification and refining, and the development of high efficiency process equipment and reactor technologies, with projects progressing from laboratory proof of concept through pilot scale validation and industrial implementation.

Dr. Miskovic received her Ph.D. in Minerals Engineering from Virginia Tech in 2011 and holds M.Sc. and B.Sc. degrees from the University of Novi Sad. She serves as Chief Technology Officer of Novex, ARR’s downstream metallization technology partner, and holds an academic appointment at the University of British Columbia’s Norman B. Keevil Institute of Mining Engineering.

ADVANCING THE MINE TO MAGNET STRATEGY

Dr. Miskovic’s appointment reinforces the technical bench advancing Halleck Creek from resource to production and links directly to ARR’s strategy of building a generational U.S. domestic mine to magnet supply chain. Optimizing recovery at the front end of the flowsheet supports the delivery of separated rare earth oxides that feed into metallization, alloying, and permanent magnet production within the United States.

“Sanja brings the technical depth and operating instinct we need as we move Halleck Creek through feasibility and toward construction. Her focus on recovery and process optimization directly supports our objective of producing separated rare earth oxides in Wyoming and feeding those oxides into a domestic metallization and magnet supply chain. Her appointment strengthens an already strong technical team and reflects the continued focus on finding the best talent to advance the Halleck Creek project towards execution.”

– Mark Wall, Chief Executive Officer, American Rare Earths

“Halleck Creek is one of the most important rare earth developments in the United States, and the opportunity to shape process design and recovery decisions during feasibility is a rare one. I look forward to working with the American Rare Earths team to advance a flowsheet that delivers separated rare earth oxides efficiently and reliably, and that supports the broader ambition of a fully integrated U.S. mine to magnet supply chain.”

– Dr. Sanja Miskovic, Chief Technical Officer, Novex LLC

This announcement has been authorized for release by the Board of American Rare Earths Limited.

INVESTOR CONTACT

Investor Relations
Nick Lissolo
nlissolo@americanree.com
www.americanree.com
Stock Information
ASX: ARR
OTCQX: ARRNF
ADR: AMRRY

Media Contact:
Susan Assadi
sassadi@americanree.com
347 977 7125

Additional Investor Relations US Contact:
Beverly Jedynak
Beverly.jedynak@viriathus.com
312 943 1123


ABOUT AMERICAN RARE EARTHS LIMITED

American Rare Earths (ASX: ARR | OTCQX: ARRNF | ADR: AMRRY) is a critical minerals company at the forefront of reshaping the U.S. rare earths industry. Through its wholly owned subsidiary, Wyoming Rare (USA) Inc. (“WRI”), the company is advancing the Halleck Creek Project in Wyoming, a world class rare earth deposit with the potential to secure America’s critical mineral independence for generations. Located on Wyoming State land, the Cowboy State Mine within Halleck Creek offers cost efficient open pit mining methods and benefits from streamlined permitting processes in this mining friendly state.

With plans for onsite mineral processing and separation facilities, Halleck Creek is strategically positioned to reduce U.S. reliance on imports, predominantly from China, while meeting the growing demand for rare earth elements essential to defense, advanced technologies, and economic security. As exploration progresses, the project’s untapped potential on both State and Federal lands further reinforces its significance as a cornerstone of U.S. supply chain security. In addition to its resource potential, American Rare Earths is committed to environmentally responsible mining practices and continues to collaborate with U.S. Government supported R&D programs to develop innovative extraction and processing technologies for rare earth elements. Further information is available at www.americanree.com.

Collaboration with NCI’s Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001
in new indications and combination regimens

IMUNON retains ownership of its background intellectual property with an opportunity to expand its IP through this collaboration

LAWRENCEVILLE, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health. Under the CRADA, IMUNON and the NCI’s Cancer Therapy Evaluation Program (CTEP) who assumes regulatory sponsorship will support further clinical and non-clinical development of IMNN-001, the Company’s DNA-based IL-12 immunotherapy, under the NCI Experimental Therapeutics (NExT) Program managed by CTEP. IMNN-001 is the first gene-based immunotherapy selected by NCI/CTEP for partnered clinical development under a CRADA.

Under the agreement, NCI investigators will evaluate IMNN-001 in new solid tumor indications and combination regimens, building on clinical data from the Company’s ongoing ovarian cancer program. IMUNON will retain ownership of its background intellectual property and will retain ownership of new intellectual property solely generated by IMUNON under the collaboration, including the right to use the data generated under the collaboration for the research and development of IMNN-001. For IMUNON, the collaboration provides an opportunity to leverage the NCI resources for generating additional clinical data for IMNN-001 in new indications.

“We believe our CRADA with NCI’s CTEP will explore the broad potential of IMNN-001 and our TheraPlas® platform,” said Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON. “This partnership allows us to efficiently explore new indications and combinations through the expertise of CTEP and the National Clinical Trials Network (NCTN) utilizing the centralized clinical trial infrastructure funded by NCI, while keeping our team fully focused on advancing our pivotal Phase 3 OVATION 3 study in frontline ovarian cancer as rapidly as possible.”

“The mechanistic rationale for IL-12 as a multipotent immune activator extends well beyond ovarian cancer, and this collaboration gives us a capital-efficient way to initiate additional clinical trials for IMNN-001 across diverse solid tumor types and indications,” said Douglas V. Faller, M.D., Ph.D., Executive Vice President and Chief Medical Officer of IMUNON.

IMNN-001 is currently being evaluated in IMUNON’s pivotal Phase 3 OVATION 3 trial in frontline advanced ovarian cancer, following encouraging results from the completed Phase 2 OVATION 2 study, in which IMNN-001 was associated with a 14.7-month increase in median overall survival compared to chemotherapy alone (45.1 vs. 30.4 months).

About IMNN-001 Immunotherapy

Designed using IMUNON’s proprietary TheraPlas® platform technology, IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that enables cell transfection followed by persistent, local secretion of the IL-12 protein. IL-12 is one of the most active cytokines for the induction of potent anticancer immunity, acting through the induction of T-lymphocyte and natural killer cell proliferation. IMUNON previously reported positive results from the completed Phase 2 OVATION 2 Study, which assessed IMNN-001 plus neoadjuvant and adjuvant chemotherapy compared to standard-of-care chemotherapy alone in 112 patients with newly diagnosed advanced ovarian cancer. IMNN-001 is now being evaluated in the Company’s pivotal Phase 3 OVATION 3 trial, enrolling patients with newly diagnosed advanced ovarian cancer at clinical sites across the U.S.

About IMUNON

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.

The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials, including one Phase 2 clinical trial (OVATION 2), and is currently conducting a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.

Forward-Looking Statements

IMUNON wishes to inform readers that forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding expectations regarding the timing and enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investors Contact:
Valter Pinto
KCSA Strategic Communications
212-896-1254
imunon@kcsa.com

TKM Grupp AS informed the stock exchange on 11 March 2026 of the completion of a transaction pursuant to which the Group’s subsidiary TKM Auto OÜ acquired 100% of the shares in Rohe Auto AS, 100% of the shares in SKO Motors OÜ and 100% of the shares in SKO Motors Kinnisvara OÜ. Rohe Auto AS and SKO Motors OÜ, acquired through the transaction, have been integrated into the Group’s car segment thereby strengthening the Group’s position in the Estonian automotive market. As a result of the transaction, the Group became the largest Škoda dealer in the Baltics.

Considering the corporate structure and business segments of TKM Grupp AS, it has been decided to merge SKO Motors Kinnisvara OÜ, the real estate company acquired as part of the above-mentioned transaction, with TKM Kinnisvara AS, which belongs to the Group’s real estate segment. To this end, a merger will be carried out whereby TKM Kinnisvara AS (as the acquiring company) will merge SKO Motors Kinnisvara OÜ (as the company being acquired) into itself.

Today, the parties signed the merger agreement in connection with the above-mentioned merger. The merger is expected to be registered in the Commercial Register in November 2026.

Raul Puusepp
Chairman of the Board
Phone: +372 731 5000
info@tkmgrupp.ee

RISHON LE ZION, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) — BOS Better Online Solutions Ltd. (“BOS” or the “Company”) (NASDAQ: BOSC), an integrator of supply chain technologies for the aerospace, defense, industrial and retail sectors, announced today that it will release financial results for the third quarter of 2026 before the market opens on Monday, November 30, 2026.

Additionally, BOS will host a video conference call on November 30, 2026, at 8:30 a.m. Eastern Time. A question-and-answer session will follow management’s presentation.

To access the video conference meeting, please click on the following link:

https://us06web.zoom.us/j/88403627595?pwd=IvzvcHZooR8CiO7jY4tap56J04OdSQ.1

For those unable to participate in the video conference, a recording of the meeting will be available the next day on the BOS website: www.boscom.com

About BOS

BOS integrates cutting-edge technologies to streamline and enhance supply chain operations for global customers in the aerospace, defense, industrial and retail sectors. The Company operates three specialized divisions:

Supply Chain Division
Distributes and integrates franchised electronic components directly into customer products.

RFID Division
Optimizes customers’ inventory management through state-of-the-art marking and tracking solutions, ensuring real-time visibility and control.

Intelligent Robotics Division
Automates industrial and logistics inventory processes through advanced robotics technologies, improving efficiency and precision.

For more information on BOS Better Online Solutions Ltd., visit www.boscom.com.

Contacts:

Eyal Cohen, CEO
BOS | +972-542525925 | eyalc@boscom.com

Safe Harbor Regarding Forward-Looking Statements

The forward-looking statements contained herein reflect management’s current views with respect to future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties that could cause the actual results to differ materially from those in the forward-looking statements, all of which are difficult to predict and many of which are beyond the control of BOS. These risk factors and uncertainties include, amongst others, the dependency of sales being generated from one or a few major customers, the uncertainty of BOS being able to maintain current gross profit margins, inability to keep up or ahead of technology and to succeed in a highly competitive industry, inability to maintain marketing and distribution arrangements and to expand our overseas markets, uncertainty with respect to the prospects of legal claims against BOS, the effect of exchange rate fluctuations, general worldwide economic conditions, the effect of the ongoing armed conflict and security conditions in Israel and in the region, the continued availability of financing for working capital purposes and to refinance outstanding indebtedness, the risk that a customer order, including the order described herein, may be delayed, modified, or canceled prior to completion of delivery; and additional risks and uncertainties detailed in BOS’ periodic reports and registration statements filed with the US Securities and Exchange Commission. BOS undertakes no obligation to publicly update or revise any such forward-looking statements to reflect any change in its expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

PRESS RELEASE
Paris, 10 September, 2026

Information on the total number of voting rights
and shares forming the share capital

(Article L.233-8 II of the French Commercial Code and
Article 223-16 of the General Regulation of the French Financial Markets Authority)

Date Issued capital Par value Total number of shares Total number of voting rights
Theoretical* Exercisable**
 

August 31, 2026

 

€ 245,607,624 € 1 245,607,624 276,893,345 272,826,627

*In accordance with Article 223-11 of the General Regulation of the French Financial Markets Authority, the total number of theoretical voting rights is calculated on the basis of all shares to which voting rights are attached, including shares deprived of voting rights.
**The total number of exercisable voting rights is calculated without taking into account shares deprived of voting rights.


About Valeo

As a technology company and partner to all automakers and new mobility players, Valeo is innovating to make mobility cleaner, safer and smarter. Valeo enjoys technological and industrial leadership in electrification, driving assistance systems, reinvention of the interior experience and lighting everywhere. These four areas, vital to the transformation of mobility, are the Group’s growth drivers.

Valeo in figures: 20.9 billion euros in sales in 2025 | 100,216 employees, 29 countries, 149 plants, 59 research and development centers, 18 distribution platforms at December 31, 2025.

Valeo is listed on the Paris Stock Exchange.  

Attachment

Transaction in Own Shares

September 09, 2026

• • • • • • • • • • • • • • • •

Shell plc (the ‘Company’) announces that on 09 September 2026 it purchased the following number of Shares for cancellation.

Aggregated information on Shares purchased according to trading venue:

Date of Purchase Number of Shares purchased Highest price paid Lowest price paid Volume weighted average price paid per share Venue Currency
09/09/2026 895,000 £ 35.4500 £ 34.9700 £ 35.2051 LSE GBP
09/09/2026 125,712 £ 35.1100 £ 34.9800 £ 35.0574 Chi-X (CXE) GBP
09/09/2026 – – – – BATS (BXE) GBP
09/09/2026 500,000 € 41.3700 € 40.8500 € 41.1095 XAMS EUR
09/09/2026 – – – – CBOE DXE EUR
09/09/2026 – – – – TQEX EUR

These share purchases form part of the on- and off-market limbs of the Company’s existing share buy-back programme previously announced on 30 July 2026.

In respect of this programme, Goldman Sachs International will make trading decisions in relation to the securities independently of the Company for a period from 30 July 2026 up to and including 23 October 2026.

The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market. The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein. The programme will be conducted in accordance with Chapter 9 of the UK Listing Rules and Article 5 of the Market Abuse Regulation 596/2014/EU dealing with buy-back programmes (“EU MAR”) and EU MAR as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020)  through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time (“UK MAR”) and the Commission Delegated Regulation (EU) 2016/1052 (the “EU MAR Delegated Regulation”) and the EU MAR Delegated Regulation as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time.

In accordance with EU MAR and UK MAR, a breakdown of the individual trades made by Goldman Sachs International on behalf of the Company as a part of the buy-back programme is detailed below.

Enquiries:

Media International: +44 (0) 207 934 5550; U.S. and Canada: https://www.shell.us/about-us/news-and-insights/media/submit-an-inquiry.html

 

Attachment

Visit Gix Internet website: https://www.gix-internet.com/

TEL AVIV, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) — Gix Internet Ltd. (Nasdaq: GIXI; TASE: GIX), a dual-listed technology company, today announced the launch of its new corporate website. The website presents the Company’s strategy of developing one intelligent, AI-powered management and orchestration software layer designed to coordinate an organization’s autonomous robots and the people working alongside them. The goal is to provide one common operating environment for robots, people and autonomous systems. Gix’s wholly owned subsidiary, Deliverz.ai, currently deploys this technology in hospital logistics.

The new website is designed to provide hospitals, potential partners and investors with information regarding the Company’s technology, its current commercial deployment and the Company’s plans for potential expansion into additional markets. Gix’s digital advertising activities are conducted through Quantum X Labs Inc., a separately listed company in which Gix holds a strategic minority interest.

Deliverz.ai assigns, manages and tracks internal deliveries of medications, samples and supplies in real time. It coordinates autonomous robots and human transport teams through a single intelligent management layer and is designed to work with existing hospital infrastructure, including elevators, doors and access control. The platform is robot-agnostic, so hospitals can run a hybrid workforce of machines and people without replacing one for the other. Gix’s broader strategy is to create one intelligent management and orchestration layer for physical operations — connecting robots, people and, over time, additional autonomous systems through one control environment. The Company believes that hospital logistics represents an initial commercial application of the platform and that the technology may ultimately be adaptable to other complex operating environments.

At Sheba Medical Center, ranked among the world’s leading hospitals, Deliverz.ai has been in continuous commercial use since December 2025, and, as of the date hereof, has completed more than 7,000 autonomous missions. In the oncology workflow between the pharmacy and treatment units, the deployment cut chemotherapy delivery time from 40 minutes to 14 minutes. Following a successfully completed pilot, Sheba selected Deliverz.ai under a public tender that provides for the potential deployment of up to 30 robots.

In July 2026, Deliverz.ai announced it was introducing the same approach to healthcare organizations in the United States.

Deliverz.ai holds two granted patents in physical-AI navigation, registered in Israel, Europe and Korea, with applications under review in the United States and Japan.

“Our dual listing on Nasdaq and the Tel Aviv Stock Exchange provides Gix with access to a broader investor audience,” said Amir Nardimon, Chief Executive Officer of Gix Internet. “We believe that the launch of our new website is an important step in presenting our technology, commercial operations and growth strategy more clearly to hospitals, potential partners and investors.”

Nardimon added: “Hospitals manage complex internal logistics involving medications, samples and supplies. Our platform is designed to coordinate autonomous robots and human transport teams through a single operating layer. Building on our commercial deployment at Sheba Medical Center, we are pursuing opportunities to introduce this technology to healthcare organizations in the United States.”

Nardimon continued: “Our vision goes beyond managing an individual robot or automating a single workflow. We are building one intelligent management layer for robots, people and autonomous systems – a common operating environment that can decide what needs to move, who or what should perform the task, and how the operation should be coordinated in real time. Healthcare is where we have first proven this approach commercially, but we believe the same management architecture can ultimately be relevant to many complex physical environments.”

The new website is at: https://www.gix-internet.com/

About Gix Internet Ltd.

Gix Internet Ltd. is listed on the Tel Aviv Stock Exchange and, as of September 1, 2026, on the Nasdaq Capital Market under the symbol GIXI. Its operating focus is Deliverz.ai, a wholly owned company that develops an AI-powered management and orchestration layer for robots, people and autonomous systems, commercially proven today in hospital logistics. The platform combines management software with autonomous mobile robots and human couriers to schedule and assign internal deliveries in real time – by location, priority and availability – from a central operations system. It is built for last-mile movement inside complex, high-traffic facilities such as hospitals, is in commercial use at Sheba Medical Center, and is being introduced to U.S. healthcare organizations. Gix’s broader strategy is to extend the same management architecture to additional autonomous systems and complex physical operating environments. Gix also holds a strategic minority stake in Quantum X Labs Inc., a separately listed company. For more information, visit https://www.gix-internet.com/.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Gix;s strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses its strategy of developing and expanding its AI-powered orchestration platform, the potential expansion of its technology into additional markets and operating environments, the anticipated capabilities and benefits of its platform, the potential deployment of additional robots pursuant to the Sheba Medical Center tender, the introduction and commercialization of its technology in the United States, and its growth strategy and future business opportunities. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s registration statement of Form 20-F (File No. 001-43362), as amended, as filed with the SEC on June 18, 2026, and in subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Gix is not responsible for the content of third-party websites.

Investor Relations Contact:

Michal Efraty
Investor Relations
michal@efraty.com

300% plus increase in six-month net income to $7.12 per share

Record revenues of $550 million in first half of 2026

Net income of $4.40 per share in Q2 2026

$3.6 billion in minimum contracted revenue

Dynamic growth of 26 vessels under construction, seven of which already delivered

$1.50 in common stock dividends paid in 2026

Tanker Market Fundamentals Remain Strong

ATHENS, Greece, Sept. 10, 2026 (GLOBE NEWSWIRE) — TEN, Ltd (NYSE: TEN) (the “Company”) today reported results (unaudited) for the six months and the second quarter ended June 30, 2026.

FIRST HALF 2026 SUMMARY RESULTS
TEN’s fleet generated record gross revenues of $551.4 million, an increase of $161.0 million compared to the first half of 2025.

Adjusted EBITDA for the first half of 2026 was at approximately $324.1 million from $193.2 million in the first six months of 2025.

The net income for the first half of 2026 reached $228.1 million (including $38 million in capital gains), equivalent to $7.12 per share from $1.70 per share in the equivalent 2025 six-month period, an increase of 318%.

Fleet utilization remained unchanged from the corresponding period in 2025 at 96.5%.

The average Time Charter Equivalent (TCE) per vessel per day for the first half of 2026 rose to $43,503, compared with $30,754 in the first half of 2025, representing a 41% increase, driven by the continued strength of the tanker markets.

Vessel operating expenses rose modestly and in line with expectations to $111.0 million, from $102.3 million in the first half of 2025, primarily due to six vessels undergoing scheduled drydocking’s, one being an LNG carrier during the first half of 2026.

Total operating expenses per vessel per day remained at a still competitive $10,298.

Depreciation and amortization totaled $90.4 million, attributable to the operation of newer and larger vessel classes to the fleet.

Total bank debt as of June 30, 2026 was $2.0 billion from $1.8 billion at December 31, 2025, reflecting fleet growth. TEN’s cash balances increased to $466.1 million, $168.0 million higher than the end of December 2025.

Interest and finance costs for the first half of 2026 amounted to $43.4 million, $5.6 million lower than the 2025 first-half level, the result of lower spreads and lower global interest rates achieved on new and refinanced loans. These costs were partially offset by interest income received in the first half of 2026 of $5.6 million.

Q2 2026 SUMMARY RESULTS
TEN’s gross revenues during the second quarter of 2026 reached $298.4 million, an increase of $105.1 million, or 54%, over the corresponding period in 2025.

Adjusted EBITDA for the second quarter of 2026 increased to $170.4 million, 81% higher than the 2025 second quarter level.

Net income in the second quarter of 2026 reached $139.3 million (inclusive of $38 million capital gains), equivalent to $4.40 per share, from $0.67 per share in the second quarter of 2025 which had no capital gains, an increase of 500% plus.

Average TCE per vessel per day in the second quarter of 2026 reached $46,100, 50% higher than the equivalent 2025 period, supported by high fleet utilization rates of nearly 95% amid favorable market fundamentals and geopolitical disruptions.

Fleet operating expenses amounted to $57.7 million, just $5.0 million above the second quarter 2025 level, primarily due to four vessels, including two suezmax tankers, undergoing scheduled drydocking’s during the quarter, compared with three in the corresponding 2025 period.

As a result, operating expenses per vessel per day in the second quarter of 2026 were $10,640.

Depreciation and amortization expenses during the second quarter of 2026 were in line with the increased number of vessels in the fleet at $46.3 million.

Consistent with the first half trend, interest and finance costs in the second quarter of 2026 decreased by $2.3 million from the corresponding 2025 period to settle at $22.6 million, benefiting from lower borrowing spreads and lower global interest rates, while interest income totaled $3.4 million.

SUBSEQUENT EVENTS
As previously announced, on July 28, 2026, TEN took delivery of the DP2 suezmax shuttle tanker Anfield DP from Samsung Heavy Industries Co., Ltd in South Korea, the third in a series of 12 DP2 shuttle tankers under construction at that yard. The vessel commenced a 10-year employment to a US oil major, with charter options to extend the charter until the vessel’s 20th year anniversary. Assuming charterers employ the vessel to the maximum duration, the expected gross revenues should approach $500 million.

As part of its ongoing fleet renewal program, in August 2026 TEN concluded the sale of two 2006-built suezmax tankers, the Alaska and Archangel, for net proceeds of $100 million.

CORPORATE AFFAIRS – COMMON STOCK DIVIDEND

In July 2026, TEN distributed to common shareholders a second semi-annual dividend, amounting to $1.00 per share, following a $0.50 per share payment in February 2026. A total distribution of $1.50 per share in 2026. The Company intends to announce the first semi-annual dividend payment of 2027 in November 2026.

Since the Company’s NYSE listing in 2002, TEN has consistently demonstrated its commitment to reward shareholders, and will have distributed, until the end of 2026 over $1.0 billion in cumulative common and preferred share dividends.

CORPORATE AFFAIRS – SERIES E PREFERRED SHARES

The Company’s 9.25% Series E Preferred Shares become redeemable at the election of the Company on May 28, 2027, and the Company currently expects that it may elect to redeem, all or a portion of, such Series E Preferred Shares on the above stated date. This disclosure does not constitute a notice of redemption, and there can be no assurance as to the amount, if any, of the Series E Preferred Shares that will be redeemed.

CORPORATE STRATEGY
Geopolitical developments around the globe continue to dictate the pace of the ongoing tanker rally which, coupled with favorable market fundamentals, is creating promising conditions for a sustained healthy market going forward.

Taking advantage of the increased ton-mile demand dislocations TEN secured attractive long-term employment to meet client requirements while solidifying the Company’s significant revenue backlog.

In addition, and in line with the stated fleet renewal strategy and considering the size of the new building program, the majority of which ordered against long-term employment, TEN continues to divest from older vessels. The sale of the 2016-built VLCC Ulysses and the two 2006-built suezmax tankers Alaska and Archangel, are a testament to that approach.

With a substantial cash balance of $466 million as of June 30, 2026, which has continued to grow thereafter, the Company remains well positioned to continue its fleet renewal and increasingly reward its shareholders.

“These results underscore the strength of TEN’s diversified fleet and flexible employment strategy which along with vessel sales, affords us the ability to generate healthy cash flows to reward our shareholders, while continuing our dynamic fleet modernization,” stated Mr. George Saroglou, President of TEN. “The company’s well-timed growth program, the largest in its history, will propel TEN going forward and solidify its position as a first-choice partner to the major energy concerns,” Mr. Saroglou concluded.

TEN’s CURRENT NEWBUILDING PROGRAM

# Name Type Delivery (exp) Status Employment
CONVENTIONAL TANKERS
1 Dr Irene Tsakos Suezmax – Scrubber Fitted Q2 2025 DELIVERED Yes
2 Silia T Suezmax – Scrubber Fitted Q4 2025 DELIVERED Yes
3 Delos T MR – Scrubber Fitted Q1 2026 DELIVERED Yes
4 Dion MR – Scrubber Fitted Q1 2026 DELIVERED Yes
5 AMAZONA Panamax LR1 – Scrubber Fitted Q2 2027 Under Construction TBA
6 TBN Panamax LR1 – Scrubber Fitted Q3 2027 Under Construction TBA
7 TBN Panamax LR1 – Scrubber Fitted Q4 2027 Under Construction TBA
8 CHAIRMAN DJS VLCC – Scrubber Fitted Q4 2027 Under Construction TBA
9 TBN VLCC – Scrubber Fitted Q1 2028 Under Construction TBA
10 TBN VLCC – Scrubber Fitted Q2 2028 Under Construction TBA
11 TBN Panamax LR1 – Scrubber Fitted Q3 2028 Under Construction TBA
12 TBN Panamax LR1 – Scrubber Fitted Q3 2028 Under Construction TBA
SHUTTLE TANKERS
13 Athens 04 DP2 Shuttle Tanker Q2 2025 DELIVERED Yes
14 Paris 24 DP2 Shuttle Tanker Q3 2025 DELIVERED Yes
15 Anfield DP DP2 Shuttle Tanker Q3 2026 DELIVERED Yes
16 ARIANO SUASSUNA DP DP2 Shuttle Tanker Q3 2027 Under Construction Yes
17 ELZA SOARES DP DP2 Shuttle Tanker Q4 2027 Under Construction Yes
18 MARIA FIRMINA DP DP2 Shuttle Tanker Q1 2028 Under Construction Yes
19 CAROLINA DE JESUS DP DP2 Shuttle Tanker Q2 2028 Under Construction Yes
20 IPANEMAS DP DP2 Shuttle Tanker Q3 2028 Under Construction Yes
21 MARACANA DP DP2 Shuttle Tanker Q3 2028 Under Construction Yes
22 CORINTHIANS DP DP2 Shuttle Tanker Q4 2028 Under Construction Yes
23 DR SOCRATES DP DP2 Shuttle Tanker Q4 2028 Under Construction Yes
24 TBN DP2 Shuttle Tanker Q4 2028 Under Construction Yes
LNG CARRIERS
25 NY KNICKS LNG Carrier Q3 2028 Under Construction TBA
26 TBN LNG Carrier Q1 2029 Under Construction TBA


ABOUT TEN LTD.

Founded in Bermuda in 1993 and celebrating 33 years as a public company, 24 of which on the NYSE, TEN is one of the first and most established public shipping companies in the world. TEN’s diversified pro-forma energy fleet currently consists of 81 vessels, totaling approx. 10.5 million dwt.

FORWARD-LOOKING STATEMENTS
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. TEN undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Conference Call Details:
As announced previously, today, Thursday, September 10, 2026, at 10:00 a.m. Eastern Time, TEN will host a conference call to review the results as well as management’s outlook for the business. The call, which will be hosted by TEN’s senior management, may contain information beyond what is included in the earnings press release.

Participants should dial into the call 10 minutes before the scheduled time using the following numbers: 877- 405- 1226 (US Toll-Free Dial In) or +1 201-689-7823 (US and Standard International Dial In). Please quote “Tsakos” to the operator and/or conference ID 13762392.
Click here for additional participant International Toll-Free access numbers.

Alternatively, participants can register for the call using the call me option for a faster connection to join the conference call. You can enter your phone number and let the system call you right away. Click here for the call me option.

Simultaneous Slides and Audio Webcast:
There will also be a live, and then archived, webcast of the conference call and accompanying slides, available through the Company’s website. To listen to the archived audio file, visit our website www.tenn.gr and click on Webcasts & Presentations under our Investor Relations page. Participants to the live webcast should register on the website approximately 10 minutes prior to the start of the webcast.

For further information, please contact:

Tsakos Energy Navigation Ltd.
George Saroglou
President & COO
+30210 94 07 710
gsaroglou@tenn.gr

Investor Relations / Media
Capital Link, Inc.
Nicolas Bornozis/ Markella Kara
+212 661 7566
ten@capitallink.com

















TSAKOS ENERGY NAVIGATION LIMITED AND SUBSIDIARIES
Selected Consolidated Financial and Other Data
(In Thousands of U.S. Dollars, except share, per share and fleet data)



















Three months ended

Six months ended



June 30 (unaudited)

June 30 (unaudited)

STATEMENT OF OPERATIONS DATA
2026



2025


2026



2025


















Voyage revenues $ 298,405


$ 193,309

$ 551,367


$ 390,360


































Voyage expenses
52,126



31,917


81,972



67,980


Charter hire expense
2,646



3,321


6,032



6,603


Vessel operating expenses
57,690



52,704


110,954



102,310


Depreciation and amortization
46,295



42,089


90,443



83,220


General and administrative expenses
14,792



13,237


27,236



23,143


Gain on sale of vessels
(37,870 )


–


(37,870 )


(3,553 )

Total expenses
135,679



143,268


278,767



279,703


















     Operating income
162,726



50,041


272,600



110,657


















Interest and finance costs, net
(22,643 )


(24,978 )

(43,430 )


(48,980 )

Interest income
3,405



3,231


5,606



5,538


Other, net
(12 )


(4 )

(33 )


(23 )

Total other expenses, net
(19,250 )


(21,751 )

(37,857 )


(43,465 )

     Net income
143,476



28,290


234,743



67,192


















      Less: Net income attributable to the noncontrolling interest
(4,176 )


(1,457 )

(6,601 )


(2,648 )

Net income attributable to Tsakos Energy Navigation Limited $ 139,300


$ 26,833

$ 228,142


$ 64,544


















Effect of preferred dividends
(6,750 )


(6,750 )

(13,500 )


(13,500 )

Undistributed and distributed income allocated to non-vested restricted common stock (684 )


(313 )

(1,108 )


(513 )

Net income attributable to common stockholders of Tsakos Energy Navigation Limited $ 131,866


$ 19,770

$ 213,534


$ 50,531


Earnings per share, basic and diluted attributable to Tsakos Energy Navigation Limited common stockholders $ 4.40


$ 0.67

$ 7.12


$ 1.70


Weighted average number of shares, basic and diluted
29,972,103



29,661,103


29,972,103



29,661,103


















BALANCE SHEET DATA
June 30


December 31










2026


2025








Cash
466,143



298,129









Other assets
286,240



197,009









Vessels, net
3,155,282



3,156,075









Advances for vessels under construction
470,050



301,868









     Total assets       $ 4,377,715


$ 3,953,081

























Debt and other financial liabilities, net of deferred finance costs
2,102,177



1,920,975









Other liabilities
220,881



169,101









Stockholders’ equity
2,054,657



1,863,005









     Total liabilities and stockholders’ equity       $ 4,377,715


$ 3,953,081











































































Three months ended

Six months ended

OTHER FINANCIAL DATA
June 30

June 30



2026



2025


2026



2025


Net cash provided by operating activities $ 183,986


$ 63,794

$ 281,167


$ 115,944


Net cash provided by (used in) investing activities $ 3,763


$ (233,479 )
$ (248,312 )

$ (236,124 )

Net cash (used in) provided by financing activities $ (43,022 )

$ 107,327

$ 135,159


$ 59,088


















TCE per ship per day $ 46,100


$ 30,767

$ 43,503


$ 30,754


















Operating expenses per ship per day $ 10,640


$ 9,982

$ 10,298


$ 9,743


Vessel overhead costs per ship per day $ 2,558


$ 2,347

$ 2,370


$ 2,063




13,198



12,329


12,668



11,806


















FLEET DATA






























Average number of vessels during period
63.5



62.0


63.5



62.0


Number of vessels at end of period
64.0



63.0


64.0



63.0


Average age of fleet at end of period Years 10.5



10.2


10.5



10.2


Dwt at end of period (in thousands)
7,702



7,766


7,702



7,766


















Time charter employment – fixed rate Days 3,569



2,969


7,197



5,841


Time charter and pool employment – variable rate Days 1,263



1,771


2,731



3,518


Period employment coa at market rates Days 0



0


0



0


Spot voyage employment at market rates Days 652



708


1,165



1,507


     Total operating days
5,484



5,448


11,093



10,866


     Total available days
5,783



5,641


11,490



11,216


      Utilization
94.8 %


96.6 %

96.5 %


96.9 %

















Non-GAAP Measures

Reconciliation of Net income to Adjusted EBITDA



















Three months ended

Six months ended



June 30

June 30



2026



2025


2026



2025


















Net income attributable to Tsakos Energy Navigation Limited $ 139,300


$ 26,833

$ 228,142


$ 64,544


Depreciation and amortization
46,295



42,089


90,443



83,220


Interest Expense
22,643



24,978


43,430



48,980


Gain on sale of vessels
(37,870 )


–


(37,870 )


(3,553 )

Adjusted EBITDA $ 170,368


$ 93,900

$ 324,145


$ 193,191


















The Company reports its financial results in accordance with U.S. generally accepted accounting principles (GAAP). However, management believes that certain non-GAAP measures used within the financial community may provide users of this financial information additional meaningful comparisons between current results and results in prior operating periods as well as comparisons between the performance of Shipping Companies. Management also uses these non-GAAP financial measures in making financial, operating and planning decisions and in evaluating the Company’s performance. We are using the following Non-GAAP measures:

(i) TCE which represents voyage revenue less voyage expenses, is divided by the number of operating days less 63 days lost for the second quarter and 137 days for the first half of 2026 as a result of calculating revenue on a loading to discharge basis, compared to 84 days lost for the second quarter and 148 days for the first half of 2025.

(ii) Vessel overhead costs are General & Administrative expenses, which also include Management fees, Stock compensation expense and Management incentive award.

(iii) Operating expenses per ship per day which exclude Management fees, General & Administrative expenses, Stock compensation expense and Management incentive award.

(iv) Adjusted EBITDA. See above for reconciliation to net income.

Non-GAAP financial measures should be viewed in addition to and not as an alternative for, the Company’s reported results prepared in accordance with GAAP.

The Company does not incur corporation tax.






















Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.